SI Joint Stabilization in Long Fusion to the Pelvis
Launched by SI-BONE, INC. · Aug 19, 2019
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
This is a multicenter randomized controlled, postmarket clinical study to determine the differences between subjects undergoing standard MLF surgery with S2AI fixation in the pelvis vs the additional placement of iFuse 3-D in the bedrock configuration during MLF surgery. Subjects will be monitored for sacroiliac (SI) joint pain and at two years post surgery a CT scan will be taken to assess S2AI screw loosening or any other findings.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 21-75 at time of screening
- • 2. Patient scheduled for multilevel (\>3 levels) spinal fusion surgery with planned fixation to the pelvis using S2AI screws
- • 3. Patient has signed study-specific informed consent form
- • 4. Patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements
- Exclusion Criteria:
- 1. Indication for multilevel spine fusion surgery is any of the following:
- • 1. Congenital neuromuscular disease
- • 2. Prior pelvic fixation (i.e., patient already has S2AI or iliac bolts in place, current surgery indicated to revise this hardware)
- • 3. Grade IV spondylolisthesis
- • 2. Prior sacroiliac joint fusion/fixation on either side
- • 3. Presence of spinal cord stimulator
- • 4. Presence of severe hip pain that could impair functional and quality of life improvement from complex spine surgery
- • 5. Surgeon plans to use iliac screw for pelvic fixation
- • 6. Any known sacral or iliac pathology
- • 7. Any condition or anatomy that makes treatment with the iFuse Implant System infeasible
- • 8. Known metabolic bone disease
- • 9. Severe osteoporosis
- • 10. Known allergy to titanium or titanium alloys
- • 11. Use of medications known to have detrimental effects on bone quality and soft-tissue healing
- • 12. Neurologic condition that would interfere with postoperative physical therapy
- • 13. Current local or systemic infection that raises the risk of surgery
- • 14. Patient currently receiving or seeking short- or long-term worker's compensation and/or currently involved in injury litigation related to the SI joint or low back pain.
- • 15. Currently pregnant or planning pregnancy in the next 2 years
- • 16. Prisoner or a ward of the state.
- • 17. Known or suspected drug or alcohol abuse
- • 18. Uncontrolled psychiatric disease that could interfere with study participation
- • 19. Fibromyalgia
About Si Bone, Inc.
si-bone, Inc. is a leading medical device company specializing in innovative solutions for sacroiliac joint disorders. Focused on enhancing patient outcomes through advanced technology, si-bone develops and commercializes minimally invasive surgical products designed to alleviate chronic pain and improve mobility. With a commitment to clinical research and evidence-based practices, the company strives to provide orthopedic surgeons with effective tools that address the unmet needs of patients suffering from sacroiliac joint dysfunction. si-bone’s dedication to quality, safety, and innovation positions it at the forefront of the evolving landscape of orthopedic care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
La Jolla, California, United States
Ann Arbor, Michigan, United States
Columbus, Ohio, United States
Little Rock, Arkansas, United States
Royal Oak, Michigan, United States
Chicago, Illinois, United States
Phoenix, Arizona, United States
Minneapolis, Minnesota, United States
Aurora, Colorado, United States
Plano, Texas, United States
Fort Wayne, Indiana, United States
Richmond, Victoria, Australia
Charlotte, North Carolina, United States
San Francisco, California, United States
Buffalo, New York, United States
Magdeburg, , Germany
Seattle, Washington, United States
Stanmore, , United Kingdom
La Jolla, California, United States
Los Angeles, California, United States
Orlando, Florida, United States
Coeur D'alene, Idaho, United States
New York, New York, United States
Nashville, Tennessee, United States
Austin, Texas, United States
Fort Worth, Texas, United States
Charlottesville, Virginia, United States
Charlottesville, Virginia, United States
Richmond, Virginia, United States
Legnano, Milan, Italy
Patients applied
Trial Officials
Daniel Cher, MD
Study Director
SI-BONE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials